enGene reports Q2 2026 results, plans BLA filing for detalimogene in 2H 2026
enGene announced 54% complete response rate in LEGEND pivotal cohort and plans to initiate a Biologics License Application for detalimogene in the second half of 2026 pending FDA engagement. The company reduced workforce by 50% to preserve $285 million in cash and focus on regulatory and precommercial activities.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day